EBMT (Gratwohl) Transplant Risk Score

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
total score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • low0–1
  • intermediate2–3
  • high4–7
Direct Clinical Answer

The EBMT (Gratwohl) Transplant Risk Score calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include age. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Pre-transplant risk score for allogeneic HSCT (0-7).

Clinical Indication

The EBMT (Gratwohl) Transplant Risk Score is indicated for bedside clinical practice to support Pre-transplant risk score for allogeneic HSCT (0-7).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Sum of 5 factors; total 0-7

Input Parameters

NameTypeRequiredDescription
agestringYesPatient age
stagestringYesDisease stage
intervalstringYesTime from diagnosis to transplant
donorstringYesDonor type
sex_matchstringYesDonor-recipient sex combination

Score Interpretation & Guidance

RangeStageDescription
0–1lowLow risk
2–3intermediateIntermediate risk
4–7highHigh risk

Evidence-Based References (EBM)

  • Gratwohl A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352(9134):1087-1092.

Related calculators